BMO Capital Downgrades Abbott Laboratories to Market Perform

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Monday, February 6th. The firm owned 190,464 shares of the healthcare product maker's stock after buying an additional 154 shares during the period. Price T Rowe Associates Inc. City Holding Co. boosted its position in Abbott Laboratories by 0.7% in the third quarter. Ronna Sue Cohen now owns 90,754 shares of the healthcare product maker's stock valued at $3,838,000 after buying an additional 1,460 shares during the period. Stokes & Hubbell Capital Management LLC increased its stake in Abbott Laboratories by 1.5% in the third quarter. Searle & CO. acquired a new position in Abbott Laboratories during the third quarter valued at approximately $441,000. Analysts are forecasting earnings of $0.43 on a per share basis this quarter. Hedge funds and other institutional investors own 62.20% of the company's stock.

The share price of the company (NYSE:ABT) was up +0.47%, with a high of 45.27 during the day and the volume of Abbott Laboratories shares traded was 12277435. For ABT, the company now has $18.62 Billion of cash on the books, which is offset by $1.33 Billion current liabilities. Sales growth past 5 years was measured at -0.50%.

To view the price target ranked by analysts, ABT attains high-level price target of 52 while lower level target was 41, it can be use an indication to know how much worth stock has stored in it. Abbott Laboratories P/E (price to earnings) ratio is 63.11 and Forward P/E ratio of 16.43. The difference between the expected and actual EPS was $0/share, which represents an Earnings surprise of 0%. The firm earned $5.33 billion during the quarter, compared to analysts' expectations of $5.41 billion. Net profit margin of the company was recorded at 6.7 percent, operating profit margin was 15.3 percent, whereas gross profit margin stands at 56.8 percent. Analysts expect that Abbott Laboratories will post $2.45 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, May 15th. Abbott Laboratories's dividend payout ratio is now 113.98%. It is mentioned at the end of reports by brokers and analysts and reflects where they consider the share price will be in case predictions are correct. TheStreet upgraded shares of Abbott Laboratories from a "c+" rating to a "b" rating in a research note on Wednesday, March 8th. Royal Bank of Canada raised their price objective on shares of Abbott Laboratories from $46.00 to $50.00 and gave the stock an "outperform" rating in a report on Wednesday, March 1st.

Abbott Laboratories was downgraded to "market perform" by analysts at BMO Capital Markets.

The latest broker reports which have been released state 7 analysts have a rating of "buy", 5 analysts "outperform", 5 analysts "hold", 0 analysts "underperform" and 0 analysts "sell". Abbott Laboratories now has a consensus rating of "Buy" and a consensus target price of $48.27.

The highest price ABT stock touched in the last 12 month was $45.84 and the lowest price it hit in the same period was $36.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Heather L. Mason sold 35,700 shares of the business's stock in a transaction dated Tuesday, January 31st. They now have a Dollars 40 price target on the stock. The disclosure for this purchase can be found here.

The Relative Volume of the company is 1.39 and Average Volume (3 months) is 8.82 million. Total debt to equity ratio of the company for most recent quarter is 1.05 while Long term debt to equity ratio for same time period is 1.01.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products.